Background: Preeclamptic women and their infants have significant morbidity and mortality worldwide. Abnormal aldosterone signaling is involved in the pathogenesis of preeclampsia, and the presence of agonistic autoantibodies against the angiotensin II type 1 receptor (AT 1 -AA) during disease has been observed. The role of AT 1 -AA in aldosterone generation with or without disease and the long-term impact of AT 1 -AA circulation in blood remain unclear.
INTRODUCTION
P reeclampsia, characterized by new-onset hypertension and proteinuria, affects 5-7% of worldwide pregnancies, causing significant maternal and infantile morbidity and mortality [1] . Preeclampsia appearing after the 20th week of gestation is classified into early (<34 weeks) or late (>34 weeks) type, dependent upon the onset time of clinical manifestation and causative mechanisms [2] . Shallow trophoblast invasion with subsequent placental ischemia and hypertension is thought to be a primary inciting event of preeclampsia [2] . However, there may be other critical events.
Accumulating evidence has suggested that agonistic autoantibodies against the angiotensin II type 1 receptor (AT 1 -AA) have a role in preeclampsia. The presence of autoantibody can result in pathophysiological alterations related to preeclampsia, including shallow trophoblast invasion, human placental blood vasculature constriction, mobilization of intracellular Ca 2þ , impaired uterine perfusion, increased soluble Fms-like tyrosine kinase-1 (sFlt-1) [3] , and, as we show here, may be a cause of preeclampsia. A recent study has shown that the transfer of purified AT 1 -AA from preeclamptic women into pregnant mice contributes to hypertension and proteinuria of the mice, both of which are hallmark features of preeclampsia [4] . Significantly, AT 1 -AA is detectable before the 20th week of gestation in women with abnormal uterine perfusion [5] and persists for 18 months after delivery in women with preeclampsia [6] . Furthermore, AT 1 -AA, not restricted to pregnancy, remains detectable for an extended period in renal transplant patients with severe vascular rejection or/and malignant hypertension [7] . However, the impact of longterm circulation of AT 1 -AA in nonpregnancy remains to be determined.
In normal human pregnancy, there is an increase in cardiac output and an enlargement of circulatory volume with decreased peripheral vascular resistance [8] . A decreased level of aldosterone (ALD), one of the most important hemodynamic-regulatory hormones for plasma volume, and the resulting inadequate plasma volume expansion during pregnancy are involved in preeclampsia. Impaired ALD synthesis precedes manifestation of clinical preeclampsia [9] , correlates with preeclampsia severity, and restricts circulatory volume expansion, resulting in increased blood pressure and protein excretion [10] . Recently, some interesting findings support a model in which AT 1 -AA-mediated sFlt-1 elevation accounts for a reduction of ALD production by impairing adrenal gland vasculature in the pregnant mice with hypertension and proteinuria [11] . However, effects of AT 1 -AA on ALD production, independent of pregnancy, especially in terms of the impact of long-term circulation of AT 1 -AA, were not examined in the study, and the correlation of AT 1 -AA to ALD in preeclampsia patients remains unknown. The aim of the current study was to address the impact of AT 1 -AA on ALD production, independent of pregnancy, improving and building the working model underlying AT 1 -AAregulated ALD production under both conditions. We demonstrate that AT 1 -AA-mediated ALD secretion is a time and dose-dependent process in which long-term presence of AT 1 -AA at a high level damages ALD production via activation of AT 1 R on the adrenocortical cells, yet with an increase in ALD upon short-term exposure.
METHODS
In addition to the methods described here, an expanded 'Methods' section is available as Supplementary Methods (http://links.lww.com/HJH/A462).
Patients
The study protocol was approved by the Institutional Committee for the Protection of Human Subjects of The Third People's Hospital of Chengdu and conformed to the Declaration of Helsinki. The patients were enrolled in the study between November 2010 and 2012. As per the func- [5] ). All patients and 50 normotensive pregnant women characterized by an uncomplicated, normal-term delivery (total 152 enrolled women) were informed of the study's purpose and protocol. Participants' written consent was obtained. Preeclamptic women were diagnosed with severe preeclampsia, mild preeclampsia, and gestational hypertension on the basis of criteria set by the International Society for the Study of Hypertension in Pregnancy (ISSHP) [12] and the US National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy [13] . Patients were excluded from the study for comorbidities of pre-existing hypertension, autoimmunity, diabetes, endocrine dysfunction, cancer, chronic wasting diseases, renal injury, or implant. The diagnosis of gestational diabetes mellitus was made when two or more values exceeded the criteria of Carpenter and Coustan (8 mmol/l) using the 100-g, 3-h oral glucose tolerance test (OGTT). Blood samples for the study were obtained shortly after diagnosis and allowed to clot before centrifugation at 3000 r.p.m. for 15 min, and then stored at À808C. Table 1 lists general clinical patient data.
Determination of aldosterone, renin, angiotensin II, and AT1-AA Commercially available radioimmunoassay kits (Beijing North Institute of Biological Technology, Beijing, China) were utilized for determining plasma ALD, Ang II concentrations, and plasma renin activity (PRA) as per manufacturer's protocols. AT 1 -AA levels were measured by streptavidin-ELISA as reported previously [4, [14] [15] [16] . Briefly, a 96-well plate was coated with the synthetic peptide IHRNVFFIINTNITVCAFHYESQNSTL corresponding to residues 165-191 of the second extracellular loop of human AT 1 R, and was incubated overnight at 48C. After blocking, 50 ml of sample serum per well was added (final dilution 1 : 40 for clinical samples of patient serum, or 1 : 10 for in-vitro samples utilizing rat serum) to the plates and incubated at 378C for 90 min, followed by washing, addition of biotinylated goat antihuman IgG (1 : 1000; Santa Cruz Biotechnology, Inc., Santa Cruz, California, USA), streptavidinhorseradish peroxidase (1 : 2000; Santa Cruz Biotechnology, Inc.), and finally the substrate 2,2 0 -azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS) (Sigma-Aldrich Inc., St Louis, Missouri, USA). The optical density (OD) values were measured at 405 nm by ELISA (Spectra Max Plus, Molecular Devices, Sunnyvale, California, USA).
Discrimination of AT 1 -AA positive and negative group
The cut-off value distinguishing positive and negative samples was determined using the BIOREBA AG protocol [17] , by using the formula: Cut-off ¼ (Mean of the mean values up to the 'step' þ 3SD) Â 1.1. Briefly, the means of the two readings of each sample were sorted in ascending order in a histogram in which data classified as the background were presented as a slight linear increase of OD values. But a clear increment called 'step' distinguished potential positive samples from the preceding background values. The calculation of the cut-off indicated that the next values on the right side of the 'step' were regarded as positive serum samples. The determinations of 'step' and the cut-off value had to be done for each processed plate.
Isolation and purification of AT 1 -AA from preeclamptic women and rats Two steps isolated AT 1 -AA from the serum of preeclamptic patients or autoantibody-positive rats. Firstly, immunoglobulin G (IgG) from either serum of preeclamptic patients or rats was obtained via antihuman IgG or antirat IgG column as per manufacturer protocols (MabTrap Kit; Amersham, Piscataway, New Jersey, USA). Secondly, AT 1 -AA was purified from total human IgG or rat IgG by the peptide corresponding to second extracellular loop of human AT 1 R (AT 1 R-EC II,) sharing significant sequence homology of 92.6% with the corresponding domain of rat AT 1 R, linked to Sepharose 4B CNBr-activated gel [18] . Unbounded IgG was washed and used as nonspecific IgG (nsIgG) control group. Bounded IgG was eluted and tested for biological activity by the responses to AT 1 R-mediated constriction of thoracic aorta in vitro (see Supplementary Fig. S3 , http://links.lww.com/HJH/A462), as reported previously [19] . Rats actively immunized with sequence of human AT 1 R-EC II were used as the source of rat AT 1 -AA as previously described [19, 20] .
Chronic administration of rat AT 1 -AA into nonpregnant rats
All studies were performed upon female Wistar rats housed in a temperature-controlled room (258C) with a 12 h:12 h light : dark condition (source of rats). All experimental procedures were in accordance with the National Institute of Health Guidelines for experimental use and care for animals. All protocols were approved by the Institute of Animal Care and Use center in Capital Medical University. Purified rat AT 1 -AA (8 mg/g, Supplementary Fig. S1 , http:// links.lww.com/HJH/A462) was resuspended in saline or nsIgG and introduced into nonpregnant rats via tail vein injection (n ¼ 8, per group) [19, 20] . A booster injection was applied every 14 days (a number derived from the AT 1 -AA half-life, see Supplementary Fig. S2 , http://links.lww.com/ HJH/A462). To minimize the effect of circadian rhythm on hormone measurements, all serum and plasma were collected between 0900 and 1100 h in resting condition, 1 day prior to the booster injection.
Histopathology and immunohistochemistry
Tissue samples were collected, fixed in 10% (v/v) formalin, embedded in paraffin, and processed for immunohistochemical (IHC) staining as per standard methods [4] . AT 1 -AA was detected by horseradish peroxidase-conjugated rabbit antibody to rat IgG (1 : 200, Santa Cruz Biotechnology, Inc.).
Cell culture and treatments
NCI-H295R human adrenocortical carcinoma cells were cultured in DME/Ham's F12 (1 : 1) medium and supplemented with 5% fetal calf serum (FBS), insulin-transferrinselenium A, streptomycin (100 mg/ml), and penicillin (100 U/ml) (all from BD Bioscience, Bedford, Massachusetts, USA). Cells were maintained in a 378C humidified atmosphere (5% CO 2 ) and subcultured onto 24-well dishes at 1 Â 10 6 cells/well for subsequent treatments, including cellular viability assay using Cell Counting Kit-8 (Dojindo Molecular Technology, Japan); determination of cellular injury by lactate dehydrogenase (LDH) release (Supplementary Methods, http://links.lww.com/HJH/A462); and cellular apoptosis assays via caspase-3 activity, the measurement of which were shown as fold-change (the ratio between an initial and final value) (CaspACE Assay System; Promega, Madison, Wisconsin, USA). To assay cell viability, representative photomicrographs were recorded of cells stained with terminal deoxynucleotidyl nickend labeling (TUNEL) (Deadend fluorometric TUNEL System; Promega) [21] . The culture medium was assayed for ALD by radio-immunoassay as described previously [21] ; measurements were normalized via protein concentration of cell lysates and shown as fold-change. Prior to treatments, cells were maintained overnight in low-serum (1-2% FBS) complete medium. Measurements to determine LDH leakage were expressed as the change in absorption per minute (K, 10 -4 ). All measurements were performed in triplicate.
Statistical analysis
Results are expressed as mean AE SEM or mean AE SD. All data were subjected to statistical analysis by SPSS version 17.0 (SPSS Inc., Chicago, Illinois, USA). The chi-square test or the Fisher's exact test was used to analyze categorical variables. One-way analysis of variance (ANOVA), followed by Bonferroni post-hoc test and the Mann-Whitney test, was used to compare the mean or median of different groups. Correlation and regression analysis were performed to explore the relativity between two variables. P values less than 0.05 were considered to be statistically significant. To investigate whether AT 1 -AA is more elevated in earlyonset vs. late-onset preeclampsia, blood samples were collected from pregnant women and serum were analyzed for AT 1 -AA levels. Results of our study confirmed that patients with aberrantly elevated blood pressure had substantially increased AT 1 -AA levels compared to normotensive pregnant patients (0.669 AE 0.133 vs. 0.315 AE 0.093; P < 0.001), and significantly greater levels of AT 1 -AA in severe preeclamptic patients compared to either mild preeclamptic patients (0.780 AE 0.104 vs. 0.598 AE 0.102; P < 0.05) or women with gestational hypertension (0.632 AE 0.116; P < 0.05, Fig. 1a ), which is in good agreement with a previous study [14] . In addition, we showed that AT 1 -AA levels were significantly greater in early-onset compared to late-onset preeclampsia (0.703 AE 0.132 vs. 0.567 AE 0.111; P < 0.05, Fig. 1b) . As shown previously, for a small cohort of severe preeclamptic patients [22] , we observed that all preeclamptic women in our larger study (mild and severe preeclampsia) showed a positive correlation between the levels of AT 1 -AA and both increased SBP (r ¼ 0.556, P < 0.05; Fig. 1c ) and proteinuria (r ¼ 0.565, P < 0.001; Fig. 1d ).
Aldosterone levels are decreased in all AT 1 -AApositive hypertensive women and are inversely correlated with AT 1 -AA in early-onset preeclamptic patients with high proteinuria
In order to determine the relationship between AT 1 -AA and ALD in pregnant women, we analyzed the blood samples for ALD. We first confirmed that circulating ALD concentrations were greater in normotensive pregnancies compared to preeclamptic patients (0.5532 AE 0.07 vs. 0.254 AE 0.072 ng/ml; P < 0.001, Fig. 2a ) [9] . To further understand the role of ALD in preeclampsia, we compared early-onset to late-onset preeclamptic women, and showed that early-onset preeclamptic patients displayed increased ALD concentrations (0.3108 AE 0.047 vs. 0.243 AE 0.071 ng/ ml; P < 0.05, Fig. 2b ). Additionally, patients without proteinuria had greater ALD levels compared to hypertensive women with proteinuria (0.3027 AE 0.082 vs. 0.254 AE 0.072 ng/ml; P < 0.05, Fig. 2c ).
To stratify the distinctive features of patients with elevated AT 1 -AA, all hypertensive women were divided into AT 1 -AA-positive and AT 1 -AA-negative groups. Compared to the AT 1 -AA-negative group, the AT 1 -AA-positive group had a decreased concentration of circulating ALD (0.257 AE 0.075 vs. 0.296 AE 0.056 ng/ml; P < 0.05, Fig. 2d ). To better assess the correlation between ALD and AT 1 -AA, we analyzed their levels via simple linear regression. No correlation between circulating ALD and AT 1 -AA was seen, suggesting that there might be some other external factors needed to be considered in the linear regression analysis. On the basis of the results that lower ALD and higher AT 1 -AA levels were associated with both early-onset preeclampsia and high proteinuria, we further stratified the patients according to the gestational week of preeclampsia onset and proteinuria. A clear inverse correlation between AT 1 -AA level and circulating ALD concentration was observed among the 50 early-onset preeclamptic patients with high proteinuria (>5.0 g/24 h) (r ¼ À0.573; P < 0.001, Fig. 2e) . No correlation was observed between serum AT 1 -AA and ALD among late-onset preeclamptic women with or without high proteinuria. Confirmation that AT 1 -AA decreased aldosterone levels in pregnant rats
To validate use of a rat model for preeclampsia, purified AT 1 -AA from preeclamptic women was administered to pregnant rats on gestation day 13 (analogous to early-onset preeclamptic timing in humans) for 5 days. As shown previously [4] and confirmed in results shown in supplementary data (http://links.lww.com/HJH/A462), we confirmed that AT 1 -AA was readily detectable and remained biologically active (Fig. 3a, Supplementary Fig. S3 , http:// links.lww.com/HJH/A462); the AT 1 -AA-positive pregnant rats exhibited hypertension, impaired renal functions, and marked pathological alterations in renal histology (Supplementary Figs. S4, S5, and S6, http://links.lww.com/HJH/ A462); and the fetuses experienced intrauterine growth retardation and increased heart rates ( Supplementary Fig.  S7 , http://links.lww.com/HJH/A462). These results demonstrate that AT 1 -AA can induce the hallmarks of preeclampsia when injected into pregnant rats.
As plasma AT 1 -AA levels increased in AT 1 -AA-treated pregnant rats over 5 days of treatment (Fig. 3a) , plasma ALD concentrations decreased (0.345 AE 0.07 vs. 0.2031 AE 0.0887 ng/ml; Fig. 3b ). This decrease in ALD was accompanied by cellular atrophy and a looser arrangement in the zona glomerulosa of the adrenal cortex than in control rats (Fig. 3c) . In contrast, these abnormalities were absent in the nsIgG-injected pregnant rats.
Aldosterone levels decreased in response to increased AT 1 -AA levels in nonpregnant rats
To explore the impact of chronic administration of AT 1 -AA on ALD generation without pregnancy, a passively immunized rat model was established, harboring clinically relevant AT 1 -AA levels [clinical AT 1 -AA range in preeclamptic women (0.37-1.00 ng/ml)] (Fig. 4a) . Four weeks of rat AT 1 -AA, but not nsIgG, administration decreased ALD concentrations (0.273 AE 0.03 to 0.123 AE 0.08 ng/ml; P < 0.05, Fig. 4b ). After ceasing AT 1 -AA passive immunization on week 8, ALD 
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To further explore the basis for decreased ALD production in AT 1 -AA-positive nonpregnant rats, we isolated the adrenal glands from immunized and control rats when autoantibody levels peaked (after 8 weeks of AT 1 -AA immunization). In order to evaluate AT 1 -AA presence, adrenal cortical zona tissues were analyzed by IHC staining using the antibody against rat IgG, and demonstrated a strongly positive result compared to controls, AT 1 -AA levels of which were undetectable all the time (Fig. 4e) . These data suggested that AT 1 -AA may directly affect ALD synthesis, as evidenced by its accumulation around the zona glomerulosa layer. The presence of substantial cellular atrophy and disruption in cellular morphology in the outermost zone of the cortex of adrenal glands were observed by H&E staining in nonpregnant rats chronically injected with purified rat AT 1 -AA (Fig. 4d) . These results demonstrated that the presence of AT 1 -AA leads to cellular injury and tissue impairment in adrenal glands. In contrast, none of the nsIgG-injected rats showed significant pathological alterations of adrenal glands (Fig. 4d) . These studies demonstrated that the long-term presence of AT 1 -AA results in reduced circulating ALD levels, independent of pregnancy.
Activation of angiotensin II type 1 receptor by AT 1 -AA directly led to abnormal aldosterone generation in cultured cells in a time and dosedependent manner
To explore the mechanistic basis for abnormal ALD generation, we determined the time and dose-dependent effects of AT 1 -AA on cultured NCI-H295R human adrenocortical tumor cells. These cells of human origin were chosen as they are reliably and widely used to study ALD production responsive to AT 1 R activation [21] . The autoantibody distribution was visualized by immunofluorescence imaging and found to co-localize with AT 1 R on the plasma membrane in AT 1 -AA-treated H295R cells (Fig. 5a, Supplementary Fig. S8 , http://links.lww.com/HJH/A462). As illustrated in Fig. 5b , longer treatments (!24 h) of AT 1 -AA at higher concentrations (!1 mg/ml) inhibited cell growth (0.71 AE 0.069 vs. 1.66 AE 0.037; P < 0.001; AT 1 -AA treatment at 1 mg/ml after 48 h), accompanied by a 3.92 AE 0.49-fold increase in LDH release and a 2.11 AE 0.17-fold increase in caspase-3 activity (Fig. 5c and d) . Likewise, TUNEL assays showed that the weak fluorescent labeling observed in the nuclei of control cells was greatly increased in AT 1 -AA-treated cells (Fig. 5e) . These findings indicate an increased cellular death (necrosis and apoptosis) in AT 1 -AA-treated cells. Chronic administration of AT 1 -AA (1 mg/ml after 48 h) led to an almost two-fold decrease in secreted ALD in culture supernatant (Fig. 6a) . Consistent with earlier in-vivo animal studies [11] , the short-term presence (24 h) of AT 1 -AA at a low level (0.5 mg/ml) stimulated both cellular ALD secretion and cell growth (Fig. 6a and Fig. 5b, respectively) , mimicking the pressor function of Ang II.
Of significance, the AT 1 R antagonist, losartan, protected AT 1 -AA-treated H295R cells from cellular apoptosis, as demonstrated by a greater than 1.5-fold decrease in caspase-3 activity compared to AT 1 -AA-treated group (Fig. 6c) and a weaker positive-TUNEL staining (Fig. 5e) . Losartan was also protective against necrosis, as demonstrated by a decrease in LDH leakage and improved ALD production in the AT 1 -AA-treated group as compared to the losartantreated group (Fig. 6d and b) . These data indicate that autoantibody-induced cellular death and abnormal ALD secretion are mediated by AT 1 R activation. Lastly, increased ALD secretion that is mediated by the short-term presence of AT 1 -AA (0.5 mg/ml after 24 h) was also blocked by the receptor antagonist losartan (Fig. 6e) . Together, these findings indicate that AT 1 -AA directly affected the cellular viability and generation of ALD in a time and dose-dependent manner via AT 1 R activation in NCI-H295R cells, suggesting a mechanism by which ALD is regulated.
DISCUSSION
In this study, we show that there is a time/dose-response relationship between circulating ALD levels and the presence of AT 1 -AA levels in the blood, which is independent of pregnancy. Upon chronic infusion of AT 1 -AA into nonpregnant rats, circulating ALD concentrations dropped dramatically, which was consistent with in-vitro observations of the decrease in ALD production and increase in cellular death of adrenocortical cells after long-term exposure. In contrast, low doses of AT 1 -AA stimulated both cellular growth and ALD production upon short-term exposure. These AT 1 -AA-induced features were blocked by AT 1 R antagonist losartan, indicating that the changes in ALD production and cell viability resulted from AT 1 -AA-mediated AT 1 R activation. Overall, our present findings demonstrate a direct time and dose-dependent regulatory role of AT 1 -AA in ALD secretion, independent of pregnancy, with a short-term increase in ALD and a longterm decrease. Figure 6f details the working model of AT 1 -AA in regulating ALD production. It has been well documented that AT 1 -AA increases sFlt-1 in pregnant mice, which blocks vascular endothelial growth factor (VEGF)-mediated signaling that is important for normal endothelial function and thereby results in hypertension and renal dysfunction [4, 23] . Notably, Siddiqui et al. [11] reported that AT 1 -AA-mediated excessive sFlt-1 levels were also responsible for the adrenal gland vascular impairment and consequent ALD reduction in a pregnancy-dependent manner, which were attenuated by injection of VEGF 121 into pregnant mice. Data from our clinical study complement these animal studies, showing an inverse correlation between AT 1 -AA and ALD in women with early-onset preeclampsia, accompanied by high proteinuria. After confirming AT 1 -AA-induced ALD reduction in pregnant rats, we further explored the long-term effect of AT 1 -AA on ALD production. Independent of pregnancy, a long-lasting presence of AT 1 -AA induced a dramatic decrease in ALD levels, accompanied by morphological changes in adrenal glands of nonpregnant rats. Interestingly, such levels and time of exposure are similar to the presence of AT 1 -AA in the sera of essential hypertension patients [24, 25] . We also observed an obvious antibody accumulation around the zona glomerulosa layer after 8 weeks of AT 1 -AA exposure, suggesting that instead of via stimulating sFlt-1 generation during pregnancy, AT 1 -AA may directly regulate ALD production by activating AT 1 Rs of zona glomerulosa cells. Supporting this possibility, we provided in-vitro evidences that upon long-term exposure, a relatively high dose of AT 1 -AA resulted in cell death and impaired ALD production via activation of AT 1 Rs on NCI-H295R adrenocortical cells. It is noteworthy that the short-term AT 1 -AA treatment was determined to stimulate cellular proliferation and increase ALD levels through activating adrenal AT 1 R, consistent with the previous in-vivo animal studies by Siddiqui et al. [11] . That is because AT 1 -AA can act like a functional mimic of Ang II, and Ang II is known to stimulate ALD generation. However, accumulating evidences show that autoantibodies as larger proteins possess their chemical and physical features distinctive from corresponding receptor agonists normally comprised of less than 10 amino acids [26, 27] . Thus, one would expect that AT 1 -AA would affect ALD levels differently. On the basis of this expectation, it was not surprising to see that AT 1 -AA worked as a novel dual regulator for ALD production.
Previous results came up a working model that AT 1 -AAmediated increase in sFlt-1 is a pregnancy-specific factor responsible for reduced ALD production [11] . Here, we improve this model by showing that AT 1 -AA via activating AT 1 Rs of zona glomerulosa cells regulates ALD production in a time and dose-dependent, yet pregnancy-independent, manner. Although we did not determine the level of sFlt-1 through the whole process, it is unlikely that sFlt-1-induced adrenal gland vascular impairment may contribute to AT 1 -AA-induced ALD reduction in nonpregnant rats because the placenta, especially preeclamptic placenta, has been proved to produce sFlt-1 [3] . Moreover, we previously observed that long-term AT 1 -AA exposure did not increase endothelin-1 (ET-1) levels and damage capillary endothelium until after 9 months of immunization [28] . In contrast, ALD levels dropped significantly after simply 8 weeks of exposure. Thus, AT 1 -AA may regulate ALD through other mechanisms. It is known that some autoantibodies can regulate endocytosis of their receptors, resulting in increased and non-desensitizing receptor activation [29] . Earlier studies have shown that AT 1 -AA induces excessive Ca 2þ influx in the vascular smooth muscle cells [30] . Since Ca 2þ overload inhibits biosynthesis of ALD [31, 32] , it is possible that sustained activation of adrenal AT 1 R induced by long-term presence of AT 1 -AA attenuates AT 1 R internalization, resulting in Ca 2þ overload and consequent impairment of ALD synthesis. The role of AT 1 -AA-triggered Ca 2þ overload in ALD regulation has not been established, and further studies on autoantibody-mediated changes in adrenal AT 1 R internalization can help to clarify the underlying mechanism. Taken together, we believe that activation of adrenal AT 1 R by AT 1 -AA is not directly responsible for reduced ALD levels in pregnant rats, but participates in chronic impairment of ALD production in a pregnancy-independent manner.
Another interesting finding of this study is that AT 1 -AA was elevated in early-onset preeclampsia. Constituting approximately 5-20% of all preeclamptic cases, the early-onset subtype is a severe form of preeclampsia characterized by placental ischemia and intrauterine growth restriction due to impaired trophoblast invasion and increased placental vessel peripheral resistance [1, 2] . Furthermore, early-onset preeclamptic mothers are predisposed to a higher rate of small-for-gestational-age infants who are at an increased risk for future short and long-term complications such as metabolic disorders and cardiovascular diseases [33] . We recently reported that middleaged offspring of AT 1 -AA-positive mother rats are prone to metabolic disorders even under a normal diet [16] . Similarly, other complications [34] observed in early-onset patients, such as small fetuses with organ growth retardation [35] , can also be induced by the presence of AT 1 -AA, yet the role of AT 1 -AA during early-onset preeclampsia remains unclear. On the basis of the statistic analysis of gestational agematched cases with a larger sample size than previous studies [23, 36] , our data showed that AT 1 -AA was much more prevalent in early-onset preeclampsia. This supports the idea that AT 1 -AA may play a crucial role in the cause of early-onset preeclampsia, but not late-onset preeclampsia [33, 35] . We expect that blocking the action of AT 1 -AA may provide more significant therapeutic benefit for patients with early-onset preeclampsia. AT 1 -AA + losartan FIGURE 6 Improved ALD generation due to losartan blocking AT 1 -AA-mediated injury on NCI-H295R cells. (a) Long-term AT 1 -AA treatment at high concentration (!1 mg/ ml, 48 h) reduced ALD generation, which yet was stimulated in the short-term presence of autoantibody (0.5 mg/ml, 24 h). Compared to AT 1 -AA-treated group, losartan (10 mg/ml) induced a 1.82 AE 0.06-fold increase in ALD secretion (P < 0.05) after AT 1 -AA treatment (1 mg/ml, 48 h, b), and attenuated LDH leakage from 10. 67 AE 0.88 to 4.81 AE 0.54 Â 10 -4 (P < 0.05, d), together with a 1.58 AE 0.092-fold decrease in caspase-3 activity (c), of which the data are shown as fold change compared with the vehicle group and are the means of three independent experiments performed in mean AE SEM. (e) Short-term presence (24 h) of AT 1 -AA at 0.5 mg/ml significantly stimulated ALD production, which was prevented by AT 1 R antagonist losartan. (f) Working model of AT 1 -AA in regulating ALD production. AT 1 -AA-trigged adrenal AT 1 R activation is not directly responsible for damaged ALD production in PE. Interestingly, increased sFlt-1 levels induced by AT 1 -AA leads to vascular impairments in adrenal cortical zona, which decreases levels of ALD during pregnancy. However, long-term presence of AT 1 -AA, via directly activating adrenal AT 1 R, contributes to a reduction of ALD level during nonpregnancy. In summary, AT 1 -AA regulates ALD production independent of pregnancy, in a time and dose-dependent manner. (Ã) P < 0.05 vs. vehicle group. ALD, aldosterone; AT 1 -AA, agonistic autoantibodies against the angiotensin II type 1 receptor; PE, preeclampsial sFlt-1, soluble Fms-like tyrosine kinase-1.
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In this interesting study Yang and coworkers report that circulating AT1 autoantibody levels are increased in women with preeclampsia (particularly in those with early-onset preeclampsia) as compared to normotensive healthy pregnant women; an opposite, significant trend was found for plasma aldosterone levels. On the whole, these findings reinforce the view that impaired aldosterone synthesis may have a pivotal role in the pathogenesis of preeclampsia by altering the physiologic plasma volume expansion. Further investigations are needed to confirm and refine the observations by Yang and coworkers and, more importantly, to address the therapeutic implications of AT1 autoantibody blockade.
